EUVIMEDEUVIMED entdecken
Crossref

In Brief: Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma

The Medical Letter on Drugs and Therapeutics · 2024

DOI: 10.58347/tml.2024.1713i ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Sarcoma, Synovial. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Afamitresgene autoleucel (Tecelra – Adaptimmune), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, has received accelerated approval from the FDA for one-time treatment of adults with unresectable or metastatic synovial sarcoma who received prior chemotherapy and are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen. It is the first gene therapy to be approved in the US for treatment of synovial sarcoma. Accelerated approval of the immunotherapy was based on the overall response rate and duration of response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, SynovialHumansImmunotherapy, AdoptiveCancer VaccinesTreatment Outcome

Stichwörter der Autor:innen

Tecelraadverse effectsafamitresgene autoleuceldosagedoxorubicinefficacysafetysarcoma

Substanzen

Cancer Vaccines

Zitieren

APA

(2024). In Brief: Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1713i

Vancouver

In Brief: Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1713i

BibTeX
@article{euvimed2024,
  title = {In Brief: Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2024},
  doi = {10.58347/tml.2024.1713i}
}
Kostenlos starten →